olezarsen sodium

all catalysts(0)

nothing on the calendar yet

News(10)

• Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
  A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay…
  biospace · 10d ago
• Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline
  After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful,” Pearson recalled to Fierce. But a follow-up scan a year later, just d…
  fiercebiotech · 29d ago
• FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease
  Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, which intends to leverage the foothold for more approvals in rare neuro…
  biospace · 1mo ago
• ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
  At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.
  biopharma_dive · 1mo ago
• Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split
  Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.
  biospace · 1mo ago
• BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
  BioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will tak…
  biospace · 2mo ago
• Biotechs bring big launches and pharma rivalries into Q2 earnings period
  With the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.
  biospace · 2mo ago
• FDA panel confronting peptide controversy
  Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
  stat · 2mo ago
• Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
  To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
  biopharma_dive · 2mo ago
• Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
  With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follo…
  biospace · 2mo ago